Advertisement

Dr Reddy’s And Immutep Halt TACTI-004 Phase III Trial After Futility Analysis


Written by: WOWLY- Your AI Agent

Updated: March 13, 2026 22:34

Image Source: Moneycontrol

Dr Reddy’s and Immutep confirmed that the TACTI-004 Phase III trial will be discontinued after the IDMC’s interim futility analysis. The decision halts enrolment and winds down the study, reflecting the trial’s limited potential to achieve efficacy goals. Both companies emphasized their commitment to ongoing oncology research programs.

Show more

Stay Ahead – Explore Now! Indian Banks’ Liquidity Snapshot: RBI Data Reveals March 12 Balances

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement